高级检索
庄民, 张为民, 刘小青. 替吉奥联合紫杉醇二线治疗复发及转移性胃癌临床疗效观察[J]. 实用临床医药杂志, 2011, (15): 94-96. DOI: 10.3969/j.issn.1672-2353.2011.15.034
引用本文: 庄民, 张为民, 刘小青. 替吉奥联合紫杉醇二线治疗复发及转移性胃癌临床疗效观察[J]. 实用临床医药杂志, 2011, (15): 94-96. DOI: 10.3969/j.issn.1672-2353.2011.15.034
shu
ZHUANG Min, ZHANG Wei-min, LIU Xiao-qing. The clinical study of domestic compound Tegafur capsulecombined with Paclitaxel second-line therapy for patients with advanced or metastatic gastric cancer[J]. Journal of Clinical Medicine in Practice, 2011, (15): 94-96. DOI: 10.3969/j.issn.1672-2353.2011.15.034
Citation: ZHUANG Min, ZHANG Wei-min, LIU Xiao-qing. The clinical study of domestic compound Tegafur capsulecombined with Paclitaxel second-line therapy for patients with advanced or metastatic gastric cancer[J]. Journal of Clinical Medicine in Practice, 2011, (15): 94-96. DOI: 10.3969/j.issn.1672-2353.2011.15.034
shu

替吉奥联合紫杉醇二线治疗复发及转移性胃癌临床疗效观察

The clinical study of domestic compound Tegafur capsulecombined with Paclitaxel second-line therapy for patients with advanced or metastatic gastric cancer

    摘要
  • 摘要: 目的 回顾性分析国产替吉奥(维康达)联合紫杉醇治疗复发、转移性胃癌患者的近期疗效及毒副反应.方法 16例复发、转移性胃癌患者使用国产替吉奥联合紫杉醇二线化疗,替吉奥根据体表面积按推荐剂量口服1～14 d,紫杉醇135mg/m2第1天静脉注射,每3周重复.所有患者均接受2周期以上化疗,2周期后评价疗效及毒副反应.结果 16例患者4例部分缓解(PR),7例稳定(SD),5例进展(PD),有效率25%,临床获益率68.75%,近期毒副反应较轻.结论 替吉奥联合紫杉醇作为二线化疗方案治疗复发、转移性胃癌,临床获益率较高,值得进一步研究.

     

    • HTML全文
    • 参考文献(11)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回